"We were very disappointed that we were not able to come up with a treatment to provide to our dementia patients in the near term," Reisa Sperling, M.D., director of the Alzheimer's center at Brigham and Women's Hospital in Boston and leader of one of the studies, told the Associated Press. But she said brain imaging and spinal fluid tests are very encouraging and suggest "we were doing something to the biology of the disease." Eli Lilly has been evaluating a similar drug, solanezumab, and also found slight benefit in patients with mild AD.
Read more about the developmental history of both drugs in Psychiatric News, here and here. For new research on genetic risk factors related to cognitive decline in AD, see the September American Journal of Psychiatry.